Ivabradine Aids Symptoms of Postural Orthostatic Tachycardia Syndrome
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 12, 2025 -- Ivabradine lowers heart rate (HR) and relieves symptoms of postural orthostatic tachycardia syndrome (POTS), according to a study published online in the July issue of the Journal of Cardiovascular Pharmacology.
Michele Marchetta, M.D., from the University of Virginia in Charlottesville, and colleagues reported the effects of HR lowering with ivabradine, a selective If channel blocker, on symptom burden in patients with POTS. The analysis included 10 patients (average age, 28 years) with POTS.
The researchers found that after ivabradine treatment, there was a significant reduction in the change in HR with standing in all patients from 40 to 15 bpm, without significant changes in blood pressure. Additionally, in all patients, the Malmö score was significantly reduced from 86 to 39. There was a correlation between change in HR with standing and the change in Malmö score (R = +0.828; R2 quadratic = 0.635). Patients also reported improvement in "feeling faint," which decreased by 69 percent, and "chest pain," which decreased by 66 percent.
"The mechanisms controlling heart rate with standing appear to be dysfunctional, leading to an excessive increase in heart rate, which is in turn sensed by the brain as a 'danger' signal leading to further release of stress hormone, norepinephrine, and to symptoms that resemble anxiety and panic attacks," coauthor Antonio Abbate, M.D., Ph.D., also from University of Virginia, said in a statement. "When the heart rate is controlled with ivabradine, the loop is inhibited, and patients feel better."
One author disclosed ties to Kiniksa, Monterosa Tx, and Novo Nordisk.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes
THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...
ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...
2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes
THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.